Stock FLEX PHARMA INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights Flex Pharma Inc Nasdaq

Equities

US33938A1051

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sector Update: Health Care Stocks Rise Late Afternoon
MT
Sector Update: Health Care Stocks Advance in Afternoon Trading
MT
Top Midday Decliners
MT
Sector Update: Health Care
MT
Salarius Pharmaceuticals Says FDA Placed Cancer Treatment Trial on Partial Hold; Shares Fall
MT
Salarius Pharmaceuticals, Inc. Receives Notification from the University of Texas MD Anderson Cancer Center
CI
Clinical Data on Salarius Pharmaceuticals? Seclidemstat in Patients with Mds and Cmml Presented At the 2024 European Hematology Association Annual Meeting
CI
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Top Premarket Gainers
MT
North American Morning Briefing : Tech in Focus on -2-
DJ
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
CI
Salarius Pharmaceuticals, Inc. Announces Update on Hematologic Cancer Phase 1/2 Clinical Trial Be Conducted At the University of Texas MD Anderson Cancer Center
CI
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
CI
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Salarius Pharmaceuticals, Inc. FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients
CI
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
CI
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLRX Stock
  4. Stock
  5. News Flex Pharma Inc
  6. Highlights